NEPTIS® LC

Louvain-la-Neuve, Belgium, December 19, 2025 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology with a preeminent position in nuclear medicine, acquires ORA, a global trailblazer in radiochemistry based in Belgium.
 

This acquisition emphasizes IBA’s long-term commitment to the fast-developing and promising field of nuclear medicine. It reinforces IBA’s position at the forefront of innovation in precision oncology enabling for better diagnostic and more personalized patient therapy.
 

The combination of IBA cyclotron leadership with ORA’s cutting-edge technology provides one of the most competitive integrated solutions for hospitals and global radiopharmacy networks looking for high productivity and access to labelling of advanced radioisotopes.
 

This acquisition complements IBA’s existing nuclear medicine strategic initiatives including the co-founding of PanTera for the production of Ac-225, and the shaping of the Accelerate.EU program, as well as the ongoing collaboration with Framatome to explore opportunities in the production of At-211. It is an additional step for IBA on its journey to bring innovation in care to patients and to accelerate the translation of innovative nuclear medicine solutions from bench to bedside.
 

The transaction, for a total consideration of € 15-20 million on a cash-free, debt-free basis, is immediately accretive to IBA Technologies’ revenue and EBITDA and is expected to generate revenue synergies. Financed through IBA’s own funds and existing credit facilities, the acquisition will not have material impact on IBA’s 2025 financial guidance or mid-term outlook.
 

“Joining forces with IBA opens exciting opportunities to scale our NEPTIS^® technology and accelerate innovation in radiochemistry.” said Vincent Tadino, Founder and Chief Executive Officer of ORA. “Together, we will continue to push the boundaries of PET and therapeutic radiochemistry, ensuring our customers have access to the most advanced and reliable solutions for radiopharmaceutical production.”
 

“ORA’s acquisition accelerates our mission to deliver integrated solutions from isotope production to patient-ready therapies, making advanced cancer treatments and diagnostics more accessible worldwide” stated Charles Kumps, President of IBA RadioPharma Solutions, “I am particularly excited that Vincent will continue to lead as Chief Technology Officer of ORA, bringing his vision and deep expertise to our joint efforts.”

In 2016, our dream started to become a reality: facilitate radiosynthesis by producing ready-to-use consumables with a plug-and-play approach.
 

In 2019, we started the production of disposable tubing kits and other consumables, in its ISO7 cleanroom at Biocant, Portugal.
 

After 9 years, we are proud of what we achieved!
From a start-up to an integrated IBA company, we specialize in the development, production, and sale of disposable cassettes for radioisotopes production and cyclotron liquid target solutions used in radiometals' production.

Louvain-la-Neuve, Belgium, May 13, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the leading provider of radiopharmaceutical production solutions, today announces the launch of CASSY^®, a compact synthesizer designed to streamline radiopharmaceutical production processes. This new IBA solution is set to transform the way radiometals and radiotracers are produced.
 

CASSY^®, Compact Automated Scalable SYnthesis, enhances efficiency in radiopharmaceuticals production especially radiometals, thanks to seamless integration into laboratory workflows, user-friendly interfaces and versatility for both purification and radiolabelling.
 

Its compact design enables up to six units to be stacked in a single standard hot cell. This feature not only saves valuable space but also increases overall production potential, making it ideal for laboratories with limited space. Additionally, CASSY^®'s versatility in handling a wide range of radioisotopes ensures it meets the diverse needs of today's research and clinical requirements, providing adaptability for future innovations such as radiotheranostics.
 

CASSY^® uses specific cassettes from Fluidomica, an integrated IBA company specialized in the development, production, and sales of disposable cassettes for single use in radioisotopes and radiopharmaceuticals manufacturing. CASSY^®’s cassettes are provided with all necessary components for processes: reagents, connections, and ancillaries.
 

Charles Kumps, President of IBA RadioPharma Solutions, stated: : “The introduction of CASSY^® represents a pivotal advancement in our dedication to theranostic innovation. Leveraging state-of-the-art technology, CASSY^® is engineered to enhance the production of radiometals. I am proud to announce that CASSY^® is a game changer for radiopharmaceuticals manufacturing, delivering superior quality and more dependable results for patients.”
 

IBA continues to lead the radiopharmaceuticals industry with its dedication to innovation and excellence. The introduction of CASSY^® is a testament to the company's ongoing efforts to improve healthcare and patient outcomes worldwide.